(Q36431127)

14 August 2017

High-dose mitoxantrone with peripheral blood progenitor cell rescue: toxicity, pharmacokinetics and implications for dosage and schedule (English)

1 reference

14 August 2017

1 reference

Ballestrero A

1

1 reference

14 August 2017

Ferrando F

2

1 reference

14 August 2017

Garuti A

3

1 reference

14 August 2017

Basta P

4

1 reference

14 August 2017

Gonella R

5

1 reference

14 August 2017

Esposito M

6

1 reference

14 August 2017

Vannozzi MO

7

1 reference

14 August 2017

Sorice G

8

1 reference

14 August 2017

Friedman D

9

1 reference

14 August 2017

Puglisi M

10

1 reference

14 August 2017

Brema F

11

1 reference

14 August 2017

Mela GS

12

1 reference

14 August 2017

Sessarego M

13

1 reference

14 August 2017

Patrone F

14

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 January 1997

1 reference

British Journal of Cancer

14 August 2017

1 reference

14 August 2017

76

1 reference

14 August 2017

6

1 reference

14 August 2017

797-804

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.1997.465

14 August 2017

0 references

cites work

Clinical implications of the heterogeneity of hematopoietic progenitors elicited in peripheral blood by anticancer therapy with cyclophosphamide and cytokine(s).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228044

Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228044

Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228044

A phase I-II study of high-dose cyclophosphamide, thiotepa and escalating doses of mitoxantrone with autologous stem cell rescue in patients with refractory malignancies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228044

Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228044

Clinical pharmacology of mitoxantrone.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228044

When can the infusion period be safely ignored in the estimation of pharmacokinetic parameters of drugs in humans?

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228044

Use of in vitro dose response effects to select antineoplastics for high-dose or regional administration regimens.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228044

A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228044

Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228044

Dose escalation of mitoxantrone given with thiotepa and autologous bone marrow transplantation for metastatic breast cancer.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228044

High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228044

Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia

21 September 2018

1 reference

12 December 2020

Effect of stem cell factor (c-kit ligand), granulocyte-macrophage colony stimulating factor and interleukin 3 on hematopoietic progenitors in human long-term bone marrow cultures

1 reference

12 December 2020

Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma

1 reference

12 December 2020

Dose: a critical factor in cancer chemotherapy

1 reference

12 December 2020

Improved high-performance liquid chromatography of the new antineoplastic agents bisantrene and mitoxantrone

1 reference

12 December 2020

Disposition of mitoxantrone in cancer patients

1 reference

12 December 2020

Comparison of mitoxantrone and ametantrone in human acute myelocytic leukemia cells in culture and in bone marrow granulocyte-macrophage progenitor cells

1 reference

12 December 2020

Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy

1 reference

12 December 2020

High dose chemo-radiotherapy for sensitive tumors: is sequential better than concurrent drug delivery?

1 reference

12 December 2020

Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1997.465

1 reference

release_5msz6rurh5g4peji4k2vieo4hm

14 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5msz6rurh5g4peji4k2vieo4hm

24 November 2022

mapped directly with Wikidata item

1 reference

14 August 2017

PubMed publication ID

9310249

1 reference